WO2009021585A1 - Probiotic bacteria for rducing the occurence of symptoms of winter infections - Google Patents
Probiotic bacteria for rducing the occurence of symptoms of winter infections Download PDFInfo
- Publication number
- WO2009021585A1 WO2009021585A1 PCT/EP2008/005661 EP2008005661W WO2009021585A1 WO 2009021585 A1 WO2009021585 A1 WO 2009021585A1 EP 2008005661 W EP2008005661 W EP 2008005661W WO 2009021585 A1 WO2009021585 A1 WO 2009021585A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- probiotic bacteria
- symptoms
- lactobacillus
- infections
- group
- Prior art date
Links
- 208000024891 symptom Diseases 0.000 title claims abstract description 39
- 239000006041 probiotic Substances 0.000 title claims abstract description 33
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 33
- 241000894006 Bacteria Species 0.000 title claims abstract description 27
- 230000000529 probiotic effect Effects 0.000 title claims abstract description 27
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 25
- 239000000203 mixture Substances 0.000 claims abstract description 22
- 241000186660 Lactobacillus Species 0.000 claims abstract description 11
- 229940079593 drug Drugs 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 11
- 241000186000 Bifidobacterium Species 0.000 claims abstract description 9
- 230000009885 systemic effect Effects 0.000 claims abstract description 9
- 229940039696 lactobacillus Drugs 0.000 claims abstract description 8
- 235000013305 food Nutrition 0.000 claims description 8
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 4
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 claims description 4
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims description 4
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims description 3
- 244000199866 Lactobacillus casei Species 0.000 claims description 3
- 235000013958 Lactobacillus casei Nutrition 0.000 claims description 3
- 229940009289 bifidobacterium lactis Drugs 0.000 claims description 3
- 235000015872 dietary supplement Nutrition 0.000 claims description 3
- 235000021001 fermented dairy product Nutrition 0.000 claims description 3
- 229940017800 lactobacillus casei Drugs 0.000 claims description 3
- 206010019233 Headaches Diseases 0.000 claims description 2
- 206010049565 Muscle fatigue Diseases 0.000 claims description 2
- 208000000112 Myalgia Diseases 0.000 claims description 2
- 206010037660 Pyrexia Diseases 0.000 claims description 2
- 229940035676 analgesics Drugs 0.000 claims description 2
- 239000000730 antalgic agent Substances 0.000 claims description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 claims description 2
- 230000001754 anti-pyretic effect Effects 0.000 claims description 2
- 239000002221 antipyretic Substances 0.000 claims description 2
- 229940125716 antipyretic agent Drugs 0.000 claims description 2
- 231100000869 headache Toxicity 0.000 claims description 2
- 230000036407 pain Effects 0.000 claims description 2
- 229920000294 Resistant starch Polymers 0.000 description 4
- 206010022000 influenza Diseases 0.000 description 4
- 235000013406 prebiotics Nutrition 0.000 description 4
- 235000021254 resistant starch Nutrition 0.000 description 4
- 235000013618 yogurt Nutrition 0.000 description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 201000009240 nasopharyngitis Diseases 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 208000031729 Bacteremia Diseases 0.000 description 2
- 241001608472 Bifidobacterium longum Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 229920000057 Mannan Polymers 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 229940009291 bifidobacterium longum Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000007407 health benefit Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- LUEWUZLMQUOBSB-GFVSVBBRSA-N mannan Chemical class O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-GFVSVBBRSA-N 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 229920001277 pectin Polymers 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 244000247812 Amorphophallus rivieri Species 0.000 description 1
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 1
- 241001134770 Bifidobacterium animalis Species 0.000 description 1
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 206010014020 Ear pain Diseases 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 229920002752 Konjac Polymers 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 240000002605 Lactobacillus helveticus Species 0.000 description 1
- 235000013967 Lactobacillus helveticus Nutrition 0.000 description 1
- 241000186605 Lactobacillus paracasei Species 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 241000031670 Saccharopolyspora thermophila Species 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 229920000617 arabinoxylan Polymers 0.000 description 1
- 150000004783 arabinoxylans Chemical class 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940118852 bifidobacterium animalis Drugs 0.000 description 1
- 229940004120 bifidobacterium infantis Drugs 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 235000015155 buttermilk Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 235000012182 cereal bars Nutrition 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 235000014048 cultured milk product Nutrition 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000011850 desserts Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000007176 earache Diseases 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005428 food component Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 235000006486 human diet Nutrition 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 201000007119 infective endocarditis Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 239000000252 konjac Substances 0.000 description 1
- 235000010485 konjac Nutrition 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229940012969 lactobacillus fermentum Drugs 0.000 description 1
- 229940054346 lactobacillus helveticus Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
- A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to the use of probiotic bacteria (probiotics), especially probiotic bacteria selected from the group consisting of Lactobacillus, Bifidobacterium species and mixtures thereof to reduce the impact of winter infections in healthy adults.
- probiotic bacteria especially probiotic bacteria selected from the group consisting of Lactobacillus, Bifidobacterium species and mixtures thereof to reduce the impact of winter infections in healthy adults.
- probiotic bacteria denotes a live or attenuated bacterium, which provides specific health benefits to the host when consumed as a food component or supplement and beneficially affects the host cell by improving its microbial balance.
- Probiotics including Lactobacillus and Bifidobacillus have a Ion g history of safe use in the dairy industry (Shortt C. Trends in Food Science and Technology 10: 411 (1999)). Fermented milk products and especially yoghurt represent the main source of probiotics in human diet. The consumer awareness of probiotics is the highest in Japan with Europe coming in second and the United States a distant third (Scheinbach S. Biotechnol Adv 16: 581 (1998)). In Japan full- scale bifidus and yogurt production has a long history of safe use; beginning in 1977 with home delivery of products containing Bifidobacterium longum and S. thermophilus. By 1984 the number of fermented products in Japan had reached 20 (lchikawa. Functional Foods, Designer Foods (1993)).
- lactobacilli and bifido bacteria are extremely rare (Saxelin M, et al. CHn Infect Dis 22: 564 (1996) ; Gasser F. Bulletin de L'lnstitut Pasteur 92: 45 (1994)) and estimated to represent 0.05 % to 0.4 % of cases of infective endocarditis and bacteraemia, however a recent study found no correlation between an increased incidence of bacteraemia and increased usage of probiotic lactobacilli (Salminen S, Arvilommi H. CHn Infect Dis 32: 1577 (2001)).
- probiotic microorganisms are known to exert a positive effect on a broad range of functions related to stimulation of the host's immune system (Clancy R, Gleeson, M., Cox, A., Dorrington, M., D'Este, C 1 Callister, P., Pyne, D., Fricker, P., Pang, G., Henriksson, A. In preparation (2005)).
- bifidobacteria and lactobacilli are thought to have most beneficial effects on the human host (Orrhage K, Nord CE. Drugs Exp CHn Res 26: 95 (2000)).
- probiotic bacteria especially probiotic bacteria selected from the group consisting of Lactobacillus, Bifidobacterium species and mixtures thereof can be used to reduce the impact of winter infections in healthy adults.
- object of the present invention is the use of probiotic bacteria selected from the group consisting of Lactobacillus, Bifidobacterium species and mixtures thereof for preparing a composition which can be administered orally to reduce
- wound infections especially denotes common cold, influenzal infection and/or flu, especially to common cold, influenzal infection and/or flu occurring from November to March in the northern hemisphere and from May to September in the southern hemisphere.
- systemic symptoms of winter infections denotes symptoms such as headache, muscle ache, fatigue and/or temperature and is used in contrast to typical local symptoms such as sore or scratchy throat, hoarseness, nasal congestion, runny nose, cough, sneezing and/or ear ache.
- severe symptoms of winter infections denotes symptoms that disturb and irritate the human during a winter infection most of the time and are ranked with a "3" in a ranking system ranging from 0 to 3, whereas
- migraine denotes analgesics (painkillers to relieve (minor) aches and pains), antipyretics (drugs to reduce fever), and/or anti-inflammatory drugs.
- the probiotic bacteria are preferably selected from one or both of the following groups:
- Lactobacillus acidophilus Lactobacillus rhamnosus, Lactobacillus casei, Lactobacillus paracasei, Lactobacillus helveticus, Lactobacillus fermentum and mixtures thereof
- Bifidobacteriae Bifidobacterium infantis, Bifidobacterium longum, Bifidobacterium lactis, Bifidobacterium animalis and mixture thereof.
- Lactobacillus acidophilus is especially preferred. - A -
- the probiotic bacteria are selected from the group consisting of
- Lactobacillus acidophilus CBS 116411 (LAFTI ® L10), Lactobacillus casei CBS 116412 (LAFTI ® L26) - both deposited at the Centraal Bureau voor Schimmel Cultures at 15 October 2004 - and Bifidobacterium lactis B94 CBS 118529 (LAFTI ® B94), deposited at the Centraal Bureau voor Schimmel Cultures at 14 September 2005.
- the mentioned LAFTI ® products are obtainable at DSM Food Specialties.
- LAFTI ® B94 and LAFTI ® L26 originate from human intestinal origin, whereas LAFTI ® L10 is of dairy origin. The use of LAFTI ® L10 is especially preferred.
- the probiotic comprises a biologically pure culture of said deposited strain.
- the probiotic comprises a biologically pure culture of said deposited strain in combination with any other valuable probiotic strain.
- the composition according to the present invention may be a food composition or a dietary supplement, e.g. in form of a tablet, granule, capsule, paste, food additive, feed additive.
- a food composition are chocolate (bars), cereals and cereal bars containing said chocolate and fermented dairy products (e. g. buttermilk, soured milk, yogurt (drinks), curd, quark desserts and so on) containing said probiotic bacteria.
- the human is preferably a healthy adult, i.e. a human that is more than 16 years old and does not suffer from any known immune deficiency.
- the composition comprises a probiotic in combination with a prebiotic.
- prebiotic denotes a component, which has a favorable influence on the growth of probiotics.
- prebiotic is selected from the group consisting of pentosans (or arabinoxylans), b-glucans, pectins, and pectic polysaccharides, mannans, Case 26287
- fructo-oligosaccharides are selected from the group consisting of inulin, banana fiber, and soy fructo-oligosaccharides or soy oligosaccharides.
- Most preferred mannans are selected from the group consisting of guar gum, locust bean gum, konjac and ad xanthan gum.
- Resistant starch as used in the context of this invention includes those forms defined as RS1 , RS2, RS3, and RS4 in Brown et al (Brown, Mc Knaught and Moloney (1995) Food Australia 47:272-275). Resistant starch and modified resistant starch have been both extensively described in US 6,348,452.
- the susceptibility to respiratory infections declines with age - the age range of the screened subjects was restricted to 18 to 25 years. Furthermore only students were recruited to avoid socioeconomic factors such as the density, housing, and distribution of the study population as well as family structure and exposure to children.
- LAFTI ® L10 was taken at a daily dose of 5 x 10 9 CFU in one application. It was normally taken in the morning with breakfast (one capsule with 5 x 10 9 CFU LAFTI ® L10).This treatment was administered for 10 consecutive weeks.
- Control 663 days with a score 3
- the total occurrence with symptoms rated as 1 or 2 differs not significantly between the two groups (p >0.05).
- Control 2762 days without a symptom
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Use of probiotic bacteria selected from the group consisting of Lactobacillus, Bifidobacterium species and mixtures thereof for preparing a composition which can be ad ministered orally to reduce • the occurrence of systemic symptoms of winter infections; • the occurrence of severe symptoms of winter infections; • the use of medication during winter infections; in humans.
Description
PROBIOTIC BACTERIA FOR REDUCING THE OCCURENCE OF SYMPTOMS OF WINTER INFECTIONS
The present invention relates to the use of probiotic bacteria (probiotics), especially probiotic bacteria selected from the group consisting of Lactobacillus, Bifidobacterium species and mixtures thereof to reduce the impact of winter infections in healthy adults.
Many species of bacteria have evolved and adapted to live and grow in the human intestine. The intestinal habitat of an individual contains 300 to 500 different species of bacteria and about 1012 viable bacteria per gram of large intestine are found (Simon GL, Gorbach SL. Gastroenterology 86: 174 (1984); Borriello SP, Barclay FE. J Med Microbiol 21 : 299 (1986)). The constant interaction between the host and its microbial guests can confer important health benefits on the human host.
The term "probiotic bacteria" (or just "probiotic") as used herein denotes a live or attenuated bacterium, which provides specific health benefits to the host when consumed as a food component or supplement and beneficially affects the host cell by improving its microbial balance.
Probiotics including Lactobacillus and Bifidobacillus have a Ion g history of safe use in the dairy industry (Shortt C. Trends in Food Science and Technology 10: 411 (1999)). Fermented milk products and especially yoghurt represent the main source of probiotics in human diet. The consumer awareness of probiotics is the highest in Japan with Europe coming in second and the United States a distant third (Scheinbach S. Biotechnol Adv 16: 581 (1998)). In Japan full- scale bifidus and yogurt production has a long history of safe use; beginning in 1977 with home delivery of products containing Bifidobacterium longum and S. thermophilus. By 1984 the number of fermented products in Japan had reached 20 (lchikawa. Functional Foods, Designer Foods (1993)).
Through yoghurt, cheese and other fermented dairy products consumers have been exposed to lactic acid bacteria (LAB) without established risk for centuries and accordingly these bacteria are generally regarded as safe (GRAS) (FAO/WHO. London, Ontario, Canada (2002); Naidu AS, Bidlack WR, Clemens RA. Crit Rev Food Sci Nutr 39: 13 (1999)). Cases of infections due to
CONRRMATIONCOPY
Case 26287
lactobacilli and bifido bacteria are extremely rare (Saxelin M, et al. CHn Infect Dis 22: 564 (1996) ; Gasser F. Bulletin de L'lnstitut Pasteur 92: 45 (1994)) and estimated to represent 0.05 % to 0.4 % of cases of infective endocarditis and bacteraemia, however a recent study found no correlation between an increased incidence of bacteraemia and increased usage of probiotic lactobacilli (Salminen S, Arvilommi H. CHn Infect Dis 32: 1577 (2001)).
Several probiotic microorganisms are known to exert a positive effect on a broad range of functions related to stimulation of the host's immune system (Clancy R, Gleeson, M., Cox, A., Dorrington, M., D'Este, C1 Callister, P., Pyne, D., Fricker, P., Pang, G., Henriksson, A. In preparation (2005)). Among the major genera of colonic bacteria, bifidobacteria and lactobacilli are thought to have most beneficial effects on the human host (Orrhage K, Nord CE. Drugs Exp CHn Res 26: 95 (2000)). These microbes have been shown previously to protect against pathogens (Goldin BR, Gorbach SL Nutrition 12: 216 (1996)), to boost the immune system, protect individuals from infection (van der Waaij D, Berghuis-de Vries, J. M., Lekkerkerk-va Wees, J.E.C. J. Hyg 69: 405 (1971 )), to modify allergic responses (Vanderhoof JA, Young RJ. Ann Allergy Asthma Immunol 93: S33 (2004); Kalliomaki MA, lsolauri E. Immunol Allergy CHn North Am 24: 739 (2004); Miraglia del Giudice M, De Luca MG. J CHn Gastroenterol 38: S84 (2004)) and to exert some cancer protective effects in vitro and in vivo (Singh J, et al. Carcinogenesis 18: 833 (1997); Mclntosh GH, Royle PJ, Playne MJ. Nutr Cancer 35: 153 (1999); Wollowski I1 Rechkemmer G1 Pool-Zobel BL. Am J CHn Nutr 73: 451S (2001)).
It has now surprisingly been found that probiotic bacteria (probiotics), especially probiotic bacteria selected from the group consisting of Lactobacillus, Bifidobacterium species and mixtures thereof can be used to reduce the impact of winter infections in healthy adults.
Common virus infections such as the common cold or influenza cause a considerable economic burden due to loss in productivity and high medical costs.
Accordingly, object of the present invention is the use of probiotic bacteria selected from the group consisting of Lactobacillus, Bifidobacterium species and mixtures thereof for preparing a composition which can be administered orally to reduce
• the occurrence of systemic symptoms of winter infections;
• the occurrence of severe symptoms of winter infections;
• the use of medication during winter infections; in humans.
Case 26287
The term "winter infections" as used herein especially denotes common cold, influenzal infection and/or flu, especially to common cold, influenzal infection and/or flu occurring from November to March in the northern hemisphere and from May to September in the southern hemisphere.
The term "systemic symptoms of winter infections" as used herein denotes symptoms such as headache, muscle ache, fatigue and/or temperature and is used in contrast to typical local symptoms such as sore or scratchy throat, hoarseness, nasal congestion, runny nose, cough, sneezing and/or ear ache.
The term "severe symptoms of winter infections" as used herein denotes symptoms that disturb and irritate the human during a winter infection most of the time and are ranked with a "3" in a ranking system ranging from 0 to 3, whereas
0 = symptom has not been present in previous 24 hours;
1 = mild symptom, i.e. can be felt but it has not been disturbing or irritating;
2 = moderate symptom, has sometimes been disturbing or irritating; 3 = severe symptom, has been disturbing or irritating most of the time.
The term "medication" as used herein denotes analgesics (painkillers to relieve (minor) aches and pains), antipyretics (drugs to reduce fever), and/or anti-inflammatory drugs.
It was not to be foreseen by the person skilled in the art that the use according to the present invention would reduce the duration of common winter infections and at the same time the severity of symptoms of winter infections.
According to a preferred embodiment of the present invention, the probiotic bacteria are preferably selected from one or both of the following groups:
Lactobacillae:
Lactobacillus acidophilus, Lactobacillus rhamnosus, Lactobacillus casei, Lactobacillus paracasei, Lactobacillus helveticus, Lactobacillus fermentum and mixtures thereof
Bifidobacteriae: Bifidobacterium infantis, Bifidobacterium longum, Bifidobacterium lactis, Bifidobacterium animalis and mixture thereof.
The use of Lactobacillus acidophilus is especially preferred.
- A -
Case 26287
Even more preferred, the probiotic bacteria are selected from the group consisting of
Lactobacillus acidophilus CBS 116411 (LAFTI®L10), Lactobacillus casei CBS 116412 (LAFTI® L26) - both deposited at the Centraal Bureau voor Schimmel Cultures at 15 October 2004 - and Bifidobacterium lactis B94 CBS 118529 (LAFTI® B94), deposited at the Centraal Bureau voor Schimmel Cultures at 14 September 2005. The mentioned LAFTI® products are obtainable at DSM Food Specialties.
LAFTI® B94 and LAFTI® L26 originate from human intestinal origin, whereas LAFTI® L10 is of dairy origin. The use of LAFTI® L10 is especially preferred.
According to a preferred embodiment of the invention, the probiotic comprises a biologically pure culture of said deposited strain. According to a more preferred embodiment, the probiotic comprises a biologically pure culture of said deposited strain in combination with any other valuable probiotic strain.
Depending on the type of application and/or administration, a composition according to the present invention comprises: from 107 cfu to 1011 cfu probiotic bacteria, preferred from 108cfu to 1011 cfu probiotic bacteria, more preferred from 108cfu to 1010cfu probiotic bacteria, most preferred from 108cfu to 109 cfu probiotic bacteria (cfu = colony forming units).
Preferably the composition according to the present invention may be a food composition or a dietary supplement, e.g. in form of a tablet, granule, capsule, paste, food additive, feed additive. Preferred examples of a food composition are chocolate (bars), cereals and cereal bars containing said chocolate and fermented dairy products (e. g. buttermilk, soured milk, yogurt (drinks), curd, quark desserts and so on) containing said probiotic bacteria.
According to the present invention the human is preferably a healthy adult, i.e. a human that is more than 16 years old and does not suffer from any known immune deficiency.
According to an especially preferred embodiment of the invention, the composition comprises a probiotic in combination with a prebiotic.
The term "prebiotic" as used herein denotes a component, which has a favorable influence on the growth of probiotics. Preferably the prebiotic is selected from the group consisting of pentosans (or arabinoxylans), b-glucans, pectins, and pectic polysaccharides, mannans,
Case 26287
arabinans, galactans, fructo-oligosaccharides, resistant starch and mixture thereof. Prebiotic have been fully described in US 6,241 ,983. Most preferred fructo-oligosaccharides are selected from the group consisting of inulin, banana fiber, and soy fructo-oligosaccharides or soy oligosaccharides. Most preferred mannans are selected from the group consisting of guar gum, locust bean gum, konjac and ad xanthan gum. Resistant starch as used in the context of this invention includes those forms defined as RS1 , RS2, RS3, and RS4 in Brown et al (Brown, Mc Knaught and Moloney (1995) Food Australia 47:272-275). Resistant starch and modified resistant starch have been both extensively described in US 6,348,452.
The invention is illustrated by the following example, which should not be construed as limiting the scope of the invention.
Case 26287
Examples:
Demographic data:
Number of subjects screened: 303
Number of subjects recruited: 300 Number of subjects completing the study: 294 (Active: 148 Control: 146)
Number of subjects included into calculation :285 (Active: 142 Control: 143) Number of subjects suffering from cold/flu: 224 (79%)
In order to ensure equal risk of disease - the susceptibility to respiratory infections declines with age - the age range of the screened subjects was restricted to 18 to 25 years. Furthermore only students were recruited to avoid socioeconomic factors such as the density, housing, and distribution of the study population as well as family structure and exposure to children.
Treatments administered: The following treatments were given according to the study protocol:
LAFTI® L10 was taken at a daily dose of 5 x 109 CFU in one application. It was normally taken in the morning with breakfast (one capsule with 5 x 109 CFU LAFTI® L10).This treatment was administered for 10 consecutive weeks.
The same protocol was followed for a placebo.
Primary objective:
To assess the reduction in duration of winter infections
Secondary objective: Determination of severity of symptoms Incidence of winter-infections Number of sick-days leave
Results:
1. Intake of medication:
Active : 283 days
Control: 367 days
Overall mean: 325.0 days
Case 26287
Overall mean 325.0 days
This leads to the Chi-square value: 2*42.02/325.0 = 10.86 p-value < 0.01
Result:
Subjects of the active group take 23% less medication as compared to the control group. This reduction is statistically significant (p < 0.01 )
Mainly painkillers (paracetamol, etc) have been taken.
Conclusion:
L10 reduces the use of medication by 23% (p < 0.01)
Sum of local and systemic symptom occurrences:
Occurrences of all symptoms with score 3:
Active: 583 days with a score 3
Control: 663 days with a score 3
This leads to the Chi-square value: 2x402 /623= 5.174 p-value = 0.02
Occurrences of all symptoms with score 2:
Active: 1610 days with a score 2
Control: 1651 days with a score 2
This leads to the Chi-square value: 2x20.52 /1630.5= 0.52 p-value =0.47
Occurrences of all symptoms with score 1 :
Active: 2961 days with a score 1
Control: 2934 days with a score 1
This leads to the Chi-square value: 2x13.52 /2947.5 = 0.12 p-value=0.73)
Results:
The total occurrence with symptoms rated as 1 or 2 differs not significantly between the two groups (p >0.05).
The total occurrence with a symptom rated as 3 is significantly higher in the control group (663 days) as compared to the active group (583 days) (p=0.02).
Conclusion:
L10 reduces occurrences of severe symptoms by 11% (p=0.02)
Case 26287
Systemic symptom occurrences:
Number of days without a symptom occurrence Active: 2926 days without a symptom
Control: 2762 days without a symptom
Number of symptom occurrences: Active: 1179 occurrences
Control: 1323 occurrences
This leads to the 2x2 contingency table:
Observed Sum Expected
With Without (with+without) With Without symptom symptom symptom symptom
Active 1179 2926 4105 1254.1 2850.9
Control 1323 2762 4085 1247.9 2837.1
Sum (A+C) 2502 5688 8190 2502.0 5688.0
This leads to the Chi-square value: 75.12*(1/1254.1+1/1247.9+1/2850.9+1/2837.1) = 12.97 p-value < 0.01
Result: For the local symptoms there is no statistically significant difference between the two groups. With the systemic symptoms, the symptom occurrence is significantly higher (11%) in the placebo group (p < 0.01 )
Conclusion: L10 reduces occurrences of systemic symptoms by 11% (p < 0.01 )
Claims
1. Use of probiotic bacteria selected from the group consisting of Lactobacillus, Bifidobacterium species and mixtures thereof for preparing a composition which can be administered orally to reduce the occurrence of systemic symptoms of winter infections in humans.
2. Use according to claim 1 , characterized in that the systemic symptoms are headache, muscle ache, fatigue and/or temperature.
3. Use of probiotic bacteria selected from the group consisting of Lactobacillus,
Bifidobacterium species and mixtures thereof for preparing a composition which can be administered orally to reduce the occurrence of severe symptoms of winter infections in humans.
4. Use of probiotic bacteria selected from the group consisting of Lactobacillus,
Bifidobacterium species and mixtures thereof for preparing a composition which can be administered orally to reduce the use of medication during winter infections in humans.
5. Use according to claim 4, characterized in that the medication consists of analgesics (painkillers to relieve (minor) aches and pains), antipyretics (drugs to reduce fever), and/or anti-inflammatory drugs.
6. Use according to claim 5, characterized in that the probiotic bacteria is selected from the group consisting of Lactobacillus acidophilus CBS 116411 , Lactobacillus casei CBS 116412, and Bifidobacterium lactis B94 CBS 118529.
7. Use according to any of the preceding claims characterized in that said composition is in the form of a food or a food supplement.
8. Use according to any of the claim 7, characterized in that said composition is in the form of a fermented dairy product.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93544007P | 2007-08-13 | 2007-08-13 | |
| US60/935,440 | 2007-08-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2009021585A1 true WO2009021585A1 (en) | 2009-02-19 |
Family
ID=39737153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2008/005661 WO2009021585A1 (en) | 2007-08-13 | 2008-07-11 | Probiotic bacteria for rducing the occurence of symptoms of winter infections |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2009021585A1 (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000078322A2 (en) * | 1999-06-21 | 2000-12-28 | Vsl Pharma Limited | Combination of lactic acid bacteria and its use for the prevention and/or treatment of infections and inflammatory conditions |
| WO2001089541A1 (en) * | 2000-05-25 | 2001-11-29 | Compagnie Gervais Danone | Use of lactobacillus casei in immunostimulatory peptides |
| WO2006007526A1 (en) * | 2004-07-01 | 2006-01-19 | Bristol Myers Squibb Company | Method for preventing or treating respiratory infections and acute otitis media in infants |
| WO2006048446A1 (en) * | 2004-11-05 | 2006-05-11 | Dsm Ip Assets B.V. | Lactobacillus for preventing and/or treating chronique fatigue syndrome and associated diseases |
| WO2006048457A1 (en) * | 2004-11-05 | 2006-05-11 | Dsm Ip Assets B.V. | Probiotica and polyphenol |
| WO2006054135A1 (en) * | 2004-11-16 | 2006-05-26 | Anidral S.R.L. | Probiotic bacteria based composition and use thereof in the prevention and/or treatment of respiratory pathologies and/or infections and in the improvement of the intestinal functionality |
-
2008
- 2008-07-11 WO PCT/EP2008/005661 patent/WO2009021585A1/en active Application Filing
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000078322A2 (en) * | 1999-06-21 | 2000-12-28 | Vsl Pharma Limited | Combination of lactic acid bacteria and its use for the prevention and/or treatment of infections and inflammatory conditions |
| WO2001089541A1 (en) * | 2000-05-25 | 2001-11-29 | Compagnie Gervais Danone | Use of lactobacillus casei in immunostimulatory peptides |
| WO2006007526A1 (en) * | 2004-07-01 | 2006-01-19 | Bristol Myers Squibb Company | Method for preventing or treating respiratory infections and acute otitis media in infants |
| WO2006048446A1 (en) * | 2004-11-05 | 2006-05-11 | Dsm Ip Assets B.V. | Lactobacillus for preventing and/or treating chronique fatigue syndrome and associated diseases |
| WO2006048457A1 (en) * | 2004-11-05 | 2006-05-11 | Dsm Ip Assets B.V. | Probiotica and polyphenol |
| WO2006054135A1 (en) * | 2004-11-16 | 2006-05-26 | Anidral S.R.L. | Probiotic bacteria based composition and use thereof in the prevention and/or treatment of respiratory pathologies and/or infections and in the improvement of the intestinal functionality |
Non-Patent Citations (3)
| Title |
|---|
| DE VRESE M ET AL: "Effect of Lactobacillus gasseri PA 16/8, Bifidobacterium longum SP 07/3, B. bifidum MF 20/5 on common cold episodes: A double blind, randomized, controlled trial", CLINICAL NUTRITION, CHURCHILL LIVINGSTONE, LONDON, GB, vol. 24, no. 4, 1 August 2005 (2005-08-01), pages 481 - 491, XP004996029, ISSN: 0261-5614 * |
| HATAKKA K ET AL: "Effect of long term consumption of probiotic milk on infections in children attending day care centres: Double blind, randomised trial", BMJ. BRITISH MEDICAL JOURNAL, LONDON, GB, vol. 322, no. 7298, 2 June 2001 (2001-06-02), pages 1327 - 1329, XP009055425, ISSN: 0959-8146 * |
| TURCHET P ET AL: "Effect of fermented milk containing the probiotic Lactobacillus casei DN-114001 on winter infections in free-living elderly subjects: a randomised, controlled pilot study.", THE JOURNAL OF NUTRITION, HEALTH & AGING 2003, vol. 7, no. 2, 2003, pages 75 - 77, XP009105928, ISSN: 1279-7707 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Thomas et al. | Probiotics and prebiotics in pediatrics | |
| Gill et al. | Probiotics and human health: a clinical perspective | |
| Zago et al. | Characterization and probiotic potential of Lactobacillus plantarum strains isolated from cheeses | |
| Malaguarnera et al. | Probiotics in the gastrointestinal diseases of the elderly | |
| Sharma et al. | Probiotics: a comprehensive approach toward health foods | |
| Rauch et al. | The potential for probiotic manipulation of the gastrointestinal microbiome | |
| Mattila-Sandholm et al. | Probiotics: towards demonstrating efficacy | |
| Ismail et al. | Probiotic effects in allergic disease | |
| Bhadoria et al. | Prospects, technological aspects and limitations of probiotics–a worldwide review | |
| JP6796070B2 (en) | Foods and drinks containing indigestible components and hydrogen gas producing agents in the large intestine | |
| US20100166721A1 (en) | Probotic compositions and uses thereof | |
| US20110165127A1 (en) | Dairy-derived probiotic compositions and uses thereof | |
| Kumari et al. | Probiotics, prebiotics, and synbiotics: Current status and future uses for human health | |
| MX2008011450A (en) | Synbiotic mixture. | |
| Rovinaru et al. | Application of microencapsulated synbiotics in fruit-based beverages | |
| Yakoob et al. | Bifidobacterium sp as Probiotic agent-roles and applications. | |
| Bielecka | Probiotics in food | |
| Young et al. | Probiotic use in irritable bowel syndrome | |
| Arora et al. | Therapeutic potential of probiotics: A ray of hope or nightmare? | |
| WO2009021585A1 (en) | Probiotic bacteria for rducing the occurence of symptoms of winter infections | |
| Dastoor et al. | Probiotics for life–Part I general health perspectives | |
| Schellack et al. | Overview of prebiotics, probiotics and synbiotics | |
| Kusumitha et al. | Prebiotics and probiotics in the formulation of infant foods | |
| Tijjani et al. | Probiotics and their attributes in human health therapy | |
| Michael et al. | Chapter-5 Probiotics |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08784702 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 08784702 Country of ref document: EP Kind code of ref document: A1 |